# US 2015/0306126 A1 · Solid oral compositions based on s-adenosyl methionine and/or nadh and process for obtaining them

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0306126 A1
- Document ID: US20150306126A1
- Status: Published application
- Kind: A1
- Application number: 14/718,789
- Filed: 2015-05-21
- Published: 2015-10-29
- Earliest claimed: 2006-03-31
- Assignees: Gnosis S.p.A.
- Applicants: Gnosis SPA
- Inventors: DANIELE GIOVANNONE; CARLO DE ANGELIS
- Web page: https://patentgrep.com/patent/US20150306126A1

## CPC

- A61K 31/7076: containing purines, e.g. adenosine, adenylic acid
- A61K 9/0007: {Effervescent (A61K9/0065 takes precedence)}
- A61K 9/2009: {Inorganic compounds}
- A61K 9/2095: {Tabletting processes}
- A61K 9/282: {Organic compounds, e.g. fats}
- A61K 31/52: Purines, e.g. adenine
- A61K 31/7084: Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
- A61P 25/24: Antidepressants
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention relates to solid oral compositions based on SAMe and/or NADH or their salts in association with calcium oxide and/or calcium hydroxide and a process for obtaining them. This invention also relates to a method for stabilising a solid oral composition based on SAMe and/or NADH or their salts, making use of calcium oxide, calcium hydroxide optionally in association with malic acid, glutamic acid, xylitol, calcium sulphate hemihydrate, magnesium oxide and/or mixtures thereof. This invention also relates to the use of SAMe or its salts in association with calcium oxide and/or calcium hydroxide with the possible further addition of melatonin and/or 1-theanine and/or 1-tryptophan and/or 5-hydroxytryptophan for the treatment of depressive states.

## Claims

### Claim 1

A composition comprising SAMe and/or NADH or its salts in association with calcium oxide and optionally pharmaceutically acceptable excipients.

### Claim 2 (depends on 1)

A composition according to claim 1, in which the said SAMe is S-adenosyl methionine paratoluene sulphonate, S-adenosyl methionine-1,4-butene disulphonate, S-adenosyl methionine sulphate, S-adenosyl methionine tosylate.

### Claim 3 (depends on 1)

A composition according to claim 1, in which the SAMe is present in a quantity varying from approximately 30 to approximately 90% by weight with respect to the weight of the composition.

### Claim 4 (depends on 3)

A composition according to claim 3, in which the SAMe is present in a quantity varying from approximately 50 to 85% by weight with respect to the weight of the composition.

### Claim 5 (depends on 1)

A composition according to claim 1, in which the NADH is present in a quantity varying from approximately 1 to approximately 90% by weight with respect to the weight of the composition.

### Claim 6 (depends on 5)

A composition according to claim 5, in which the NADH is present in a quantity varying from approximately 5 to 50% by weight with respect to the weight of the composition.

### Claim 7 (depends on 1)

A composition according to claim 1, in which the calcium oxide is present in a quantity varying from approximately 1 to approximately 40% by weight with respect to the weight of the composition.

### Claim 8 (depends on 1)

A composition according to claim 1, in which the calcium oxide is present in a quantity varying from approximately 2 to approximately 20% by weight with respect to the weight of the composition.

### Claim 9 (depends on 1)

A composition according to claim 1, comprising at least one further active ingredient preferably selected from 1-melatonin, 1-theanine and/or 1-tryptophan and/or 5-hydroxytryptophan or mixtures thereof.

### Claim 10 (depends on 1)

A composition according to claim 1, in which at least one of the pharmaceutically acceptable excipients is calcium sulphate hemihydrate and/or glucono-delta-lactone.

### Claim 11

A composition according to the preceding claims, in the form of a direct mixture, tablet, capsule, granulate or powder.

### Claim 12 (depends on 1)

A composition according to claim 1, in the form of a tablet, preferably an ordinary, coated, film-coated and/or gastroresistant tablet.

### Claim 13 (depends on 1)

A composition according to claim 1, characterised in that it is in the form of a gastroresistant tablet.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

A process for the preparation of a tablet according to claims 1-13, comprising the following stages:
a) mixing of the SAMe and/or NADH and/or their salts with calcium oxide and pharmaceutically acceptable excipients,
b) precompression and subsequent granulation of the mixture obtained in stage a),
c) mixing of the granulate obtained in stage b) with pharmaceutically acceptable excipients such as calcium sulphate hemihydrate, xylitol, malic acid, glutamic acid, glucono-delta-lactone, magnesium oxide, hydrogenated fatty acids, precipitated silica, magnesium stearate, saccharose, glycerol behenate,
d) compression of the mixture obtained in stage c), with the optional addition of sweeteners and/or flavourings,
e) optional coating of the tablet obtained in stage d) with hydrogenated fatty acids,
f) optional aqueous phase film-coating of the tablet obtained in stage e).

### Claim 15 (depends on 14)

A process according to claim 14 in which the SAMe is S-adenosyl methionine paratoluene sulphonate, S-adenosyl methionine-1,4-butene disulphonate, S-adenosyl methionine sulphate, S-adenosyl methionine tosylate.

### Claim 16 (depends on 14)

A process according to claim 14, in which the said calcium oxide is calcium oxide alone.

### Claim 17 (depends on 14)

A process according to claim 14, in which the absolute moisture content is less than approximately 50%-60% and the temperature is maintained around 20° C. and 25° C., in particular around 20° C.

### Claim 18 (depends on 14)

A process according to claim 14, in which in stage c) at least one further active ingredient preferably selected from 1-melatonin, 1-theanine and/or 1-tryptophan and/or 5-hydroxytryptophan and/or mixtures thereof may be added to the mixture.

### Claim 19 (depends on 14)

A process according to claim 14, in which the coating mentioned in stage e) is applied using hydrogenated fatty acids in a quantity of between 0.4 and 1.5% by weight with respect to the weight of the tablet.

### Claim 20 (depends on 14)

A process according to claim 14, in which the aqueous phase film-forming mentioned in stage f) is performed using a varnish preferably selected from gum Lac and/or its salts (Shellac™), methacrylic acid, cellulose acetophthalates, titanium dioxide, talc, triethyl citrate, PVP K30, curcumin, lutein, hydroxypropylcellulose, hydroxypropylmethylcellulose and/or mixtures thereof.

### Claim 21 (depends on 20)

A process according to claim 20, in which the varnish lies within a range between approximately 1.0 and approximately 5.0% by weight with respect to the composition.

### Claim 22 (depends on 14, 15, 16, 17, 18, 19, 20, 21)

Compositions which can be obtained through the process in claims 14-21.

### Claim 23

A method for the treatment of depressive states which comprises the administration of SAMe or its salts in association with calcium oxide to a patient in such a need.

### Claim 24 (depends on 23)

A method according to claim 23 in which magnesium oxide is further added to the said calcium oxide.

### Claim 25 (depends on 23)

A method according to claim 23, in which the said SAMe is S-adenosyl methionine paratoluene sulphonate, S-adenosyl methionine-1,4-butene disulphonate, S-adenosyl methionine sulphate, S-adenosyl methionine tosylate.

### Claim 26 (depends on 23)

A method according to claim 23, in which the said calcium oxide is calcium oxide alone.

### Claim 27

A method for stabilising a composition based on SAMe or its salts comprising use of the mixture of SAMe and its salts with calcium oxide.

### Claim 28

A method for stabilising a composition based on NADH or its salts comprising use of the mixture of NADH and its salts with calcium oxide.

### Claim 29 (depends on 27)

A method according to claim 27, in which SAMe or its salts is present in a quantity of between approximately 30 and approximately 90% by weight calculated in relation to the weight of the composition.

### Claim 30 (depends on 27)

A method according to claim 27, in which SAMe or its salts is present in a quantity of between approximately 50 and approximately 85% by weight calculated in relation to the weight of the composition.

### Claim 31 (depends on 28)

A method according to claim 28, in which NADH or its salts is present in a quantity of between approximately 1 and approximately 90% by weight calculated in relation to the weight of the composition.

### Claim 32 (depends on 28)

A method according to claim 28, in which NADH or its salts is present in a quantity of between approximately 5 and approximately 50% by weight calculated in relation to the weight of the composition.

### Claim 33 (depends on 27, 28, 29, 30, 31, 32)

A method according to claims 27-32 in which the calcium oxide is present in a quantity which varies from approximately 1 to approximately 40% by weight with respect to the weight of the composition.

### Claim 34 (depends on 33)

A method according to claim 33, in which the calcium oxide is present in a quantity which varies from approximately 2 to approximately 20% by weight with respect to the weight of the composition.

### Claim 35 (depends on 33)

A method according to claim 33, comprising the addition of pharmaceutically acceptable excipients.
